Last edition
News about "DESTINY-Breast05 Phase 3 Trial"
EU Approves Enhertu for HER2-Positive Early Breast Cancer
The EU has approved Enhertu as adjuvant treatment for HER2-positive early breast cancer with residual disease, reducing recurrence or death risk by 53 percent vs. T-DM1.
DESTINY-Breast05 Phase 3 Trial | 28/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members